

August 14, 2013

**The Manager
Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor, Plot No: C/1
G - Block, Bandra - Kurla Complex
Bandra (East), Mumbai – 400 051**

Dear Sirs,

Sub: Unaudited Financial Results for the three months ended 30th June, 2013

In accordance with the Clause 41 of the listing agreement, we are enclosing the following


- ❖ Copy of the Unaudited Financial Results of the Company for the quarter and fifteen months ended June 30, 2013 along with the press release in this respect.
- ❖ Copy of the limited review report on the aforesaid Unaudited Financial Results as issued by the Statutory Auditors of the Company.

The above Unaudited Financial Results and the limited review report have been taken on record by the Board of Directors at their meeting held on August 14, 2013.

This is for your information and records.

Thanking you,

Yours faithfully,



**L Chandrasekar
Executive V P – Finance & Secretary.**

Encl.: a/a



UNAUDITED FINANCIAL RESULTS FOR FIFTEEN MONTHS ENDED JUNE 30, 2013

**Orchid Chemicals
& Pharmaceuticals Limited**

Rs. lakhs

S. No.	Particulars	Unaudited				Audited
		Three months ended 30-Jun-2013	Three months ended 31-Mar-2013	Three months ended 30-Jun-2012	Fifteen months ended 30-Jun-2013	Year ended 31-Mar-2012
1	Net Sales / Income from Operations (Net of Excise Duty)	24846.12	26815.67	31563.15	147632.71	170170.80
2	Other Operating Income	832.31	-	4159.90	4992.21	6293.47
3	Total Operating Income (1+2)	25678.43	26815.67	35723.05	152624.92	176464.27
4	Expenditure					
a)	Cost of materials consumed	12188.27	14903.25	10193.28	59631.26	80241.50
b)	Purchases of stock-in-trade	404.64	644.38	1538.32	5377.74	4546.38
c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(628.76)	204.75	7204.14	12479.58	(6201.86)
d)	Employees Cost	3930.45	3728.41	3761.80	19635.58	15464.59
e)	Depreciation / Amortisation	4194.80	3863.41	3991.26	19910.56	14905.56
f)	Other Expenditure	5480.61	5937.38	7444.46	37939.83	41242.32
g)	Total	25570.01	29281.58	34133.26	154974.55	150198.49
5	Profit from Operations before Other Income, Interest, Exceptional Item (3-4)	108.42	(2465.91)	1589.79	(2349.63)	26265.78
6	Other Income	-	-	-	1.31	1.59
7	Profit / (Loss) before Interest & Exceptional Item (5+6)	108.42	(2465.91)	1589.79	(2348.32)	26267.37
8	Finance cost	9524.40	8576.43	7132.59	39949.78	17905.29
9	Profit/(loss) after interest but before Exceptional Item (7-8)	(9415.98)	(11042.34)	(5542.80)	(42298.10)	8362.08
10	Exceptional Item - Gain/(Loss)	3965.49	(639.64)	(808.04)	6580.61	(8388.14)
11	Profit/(Loss) before Tax (9+10) from Ordinary activities	(5450.49)	(11681.98)	(6350.84)	(35717.49)	(26.06)
12	Tax expenses					
-	Current Tax & Deferred Tax	-	1544.86	(1270.66)	(2729.58)	(2337.22)
13	Net Profit/(Loss) after Tax (11-12)	(5450.49)	(13226.84)	(5080.18)	(32987.91)	2311.16
14	Extraordinary item- (net of tax of Rs.Nil)	-	-	-	-	8000.00
15	Net Profit/(Loss) for the period (13+14)	(5450.49)	(13226.84)	(5080.18)	(32987.91)	10311.16
16	Paid-up Equity Share Capital (Face value of Rs.10/- each)	7045.21	7045.21	7045.21	7045.21	7044.21
17	Reserves excluding Revaluation Reserves	-	-	-	-	112410.89
18	Earnings per share (EPS) before extra-ordinary item					
-	Basic Rs.*	(7.74)	(18.77)	(7.21)	(46.82)	3.28
-	Diluted Rs.*	(7.74)	(18.77)	(7.21)	(46.82)	3.24
19	Earnings per share (EPS) after extra-ordinary item					
-	Basic Rs.*	(7.74)	(18.77)	(7.21)	(46.82)	14.64
-	Diluted Rs.*	(7.74)	(18.77)	(7.21)	(46.82)	14.46
A	PARTICULARS OF SHAREHOLDING					
1	Public Shareholding					
-	Number of equity shares	47,711,295	47,711,295	47,611,295	47,711,295	47,601,295
-	Percentage of Shareholding	67.72	67.72	67.58	67.72	67.57
2	Promoters and Promoter group shareholding					
a.	Pledged / Encumbered					
-	Number of shares	18,659,262	17,616,262	17,110,383	18,659,262	17,060,383
-	Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	82.05	77.47	74.91	82.05	74.69
-	Percentage of shares (as a % of the total share capital of the company)	26.48	25.00	24.29	26.48	24.22
b.	Non - Encumbered					
-	Number of shares	4,081,519	5,124,519	5,730,398	4,081,519	5,780,398
-	Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	17.95	22.53	25.09	17.95	25.31
-	Percentage of shares (as a % of the total share capital of the company)	5.79	7.28	8.13	5.79	8.21

CERTIFIED TRUE COPY /
For ORCHID CHEMICALS & PHARMACEUTICALS LTD.

Executive Vice President - Finance & Secretary





B	PARTICULARS
	INVESTOR COMPLAINTS
	Pending at the beginning of the quarter - NIL -
	Received during the quarter 5
	Disposed of during the quarter 5
	Remaining unresolved at the end of the quarter - NIL -
	* EPS for the period (except for the year ended on March 31, 2012) is not annualised.
1	The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 14, 2013 and have been subjected to limited review by the Statutory Auditors in terms of Clause 41 of the Listing Agreement.
2	The Company is operating in single segment (i.e) "Pharmaceuticals".
3	The Company has entered into a Business Transfer Agreement (BTA) dated August 29, 2012 with Hospira Healthcare India Private Limited for the sale and transfer of Orchid's Penicillin and Penem API business and the API facility located in Aurangabad (Maharashtra) together with an associated Process R&D infrastructure located in Chennai. The transaction is expected to be completed before September 30, 2013. Accordingly the Company has extended the Financial year 2012-13 for eighteen months ending September 30, 2013 and requisite permission for extension of the Financial year has been obtained.
4	During the current quarter, the Company's Banker M/s State Bank of India has made a reference for restructuring the debts of the Company before CDR Cell. The Company is in the process of negotiation with Banks, Financial Institutions and others for settlement of dues. The amount of penal interest and other charges payable would be determined on completion of the negotiations. Hence provision for liability, if materialises, will be made on conclusion of negotiations.
5	Exceptional items for fifteen months ended June 30, 2013 represents profit on sale of land/buildings of Rs.5389.99 Lakhs, profit on sale of investments in the Joint venture in China of Rs.5333.76 Lakhs and Exchange loss of Rs.4143.14 Lakhs. Exceptional items for this quarter include profit on sale of land/buildings of Rs.5389.99 Lakhs and Exchange loss of Rs.1424.50 Lakhs.
6	The Company had exercised the option provided under the Companies (Accounting Standards) Amendment Rules, 2006 dated March 31, 2009. The Ministry of Corporate affairs vide notification dated 29/12/2011 has extended the amortisation of gains or losses arising on reporting of foreign currency monetary items over the balance period of such long term asset/liability. Accordingly exchange loss on long term foreign currency loans have been amortised over the balance period of such loans. The amount remaining to be amortised in the financial statements as at June 30, 2013 on account of exercising the above option is Rs.13868.18 Lakhs.
7	Previous period figures have been regrouped wherever necessary.
	<div data-bbox="882 1171 1098 1370" data-label="Image"> </div> <div data-bbox="1217 1205 1485 1227" data-label="Text"> <p>For and on behalf of the Board</p> </div> <div data-bbox="1249 1227 1457 1305" data-label="Text"> </div> <div data-bbox="1217 1305 1485 1361" data-label="Text"> <p>K. Raghavendra Rao Chairman & Managing Director</p> </div> <div data-bbox="172 1317 403 1373" data-label="Text"> <p>Place : Chennai Date : August 14, 2013</p> </div>



/CERTIFIED TRUE COPY/
For ORCHID CHEMICALS & PHARMACEUTICALS LTD

Executive Vice President - Finance & Secretary

SNB ASSOCIATES

CHARTERED ACCOUNTANTS

12, 3rd Floor, Gemini Parsn Complex. 121 Mount Road, Chennai - 600 006.

AUDITORS' REPORT

**TO THE BOARD OF DIRECTORS OF
ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED**

**ON LIMITED REVIEW OF UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED JUNE 30, 2013**

We have reviewed the accompanying statement of unaudited financial results of **ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED** ("the Company") for the Quarter and the period of 15 months ended 30th June 2013 except for the disclosures regarding "Public Shareholding" and "Promoter and Promoter Group Shareholding", which have been traced from disclosures, made by the management and have not been audited by us. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

- a) Provision for penal interest has been accounted only to the extent of information available with the company. In the absence of confirmations from the banks and financial institutions, we are not able to comment, whether the full provision has been made for penal interest charged by the banks and financial institutions. The company is in the process of reconciling major bank accounts and the results are subject to any entries that may be passed at the time of reconciliation.
- b) No provision has also been made by the company for penalties and interest, for non payment of statutory dues as the amounts are not determined.
- c) The company has entered into a binding agreement for sale of Aurangabad unit with Hospira and Hospira has been financing the activities relating to Aurangabad. The account with Hospira is subject to reconciliation and confirmation.




Based on our review conducted as above, subject to the previous paragraphs (a to c) above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is disclosed, or that it contains any material misstatements.

Date: 14th August 2013
Place: Chennai



For SNB ASSOCIATES
Chartered Accountants
Firm Registration No. 015682N


B. Mahalingam
Partner
Membership No. 210408

Q5 FY13 Earnings

Chennai, India - August 14, 2013

Orchid Pharma registers turnover of Rs 249 crore in Q5 FY13

Financial highlights for Quarter ended June 30, 2013 (Q5 FY13)

- Revenue of Rs 249.87 crore (US\$ 42.08 million) in the quarter ended June 30, 2013 (Q5 FY13) compared to Rs 316.60 crore (US\$ 53.31 million) in the quarter ended June 30, 2012
- EBITDA of Rs 82.69 crore (US\$ 13.93 million) in the quarter ended June 30, 2013 versus Rs 47.73 crore (US\$ 8.04 million) in the quarter ended June 30, 2012
- Loss before Tax of Rs 54.50 crore (US\$ 9.18 million) in the quarter ended June 30, 2013 compared to a loss before tax of Rs 63.51 crore (US\$ 10.69 million) during the quarter ended June 30, 2012
- At the net level, the company registered a loss (after exceptional item gain of Rs 39.65 crore) of Rs 54.50 crore (US\$ 9.18 million) in the quarter ended June 30, 2013 compared to a loss of Rs 50.80 crore (US\$ 8.55 million) during the quarter ended June 30, 2012

Financial highlights for 15-mths ended June 30, 2013


- Revenue of Rs 1476.33 crore (US\$ 248.60 million) in the 15-months ended June 30, 2013
- EBITDA of Rs 241.42 crore (US\$ 40.65 million)
- Loss before Tax (before exceptional item gain of Rs 65.81 crore) of Rs 422.98 crore (US\$ 71.23 million)
- Net loss after Tax (after exceptional item gain of Rs 65.81 crore) of Rs 357.18 crore (US\$ 60.14 million)

Financial year extension

The company has extended its financial year (FY 2012-13) by 6 months to September 30, 2013.

1 US\$ = Rs 59.39

y




'Orchid Towers' #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA



About Orchid Pharma

Orchid Chemicals & Pharmaceuticals Ltd. is a leading pharmaceutical company headquartered in Chennai, India involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. With exports spanning more than 75 countries, Orchid is the largest manufacturer-exporter of cephalosporin bulk actives in India and is ranked amongst the Top 5-cephalosporin producers in the world. Orchid's world-class manufacturing infrastructure including USFDA and UK MHRA approved API and dosage form facilities are located at Chennai and Aurangabad. Orchid has dedicated state-of-the-art GLP compliant R&D centres for API research, drug discovery and pharmaceutical research at Chennai. Orchid has ISO 9001:2000, ISO 14001 and OHSAS 18001 certifications. Orchid is listed on the National Stock Exchange (NSE), Bombay Stock Exchange (BSE) and the Madras Stock Exchange (MSE) in India.

**For ORCHID CHEMICALS &
PHARMACEUTICALS LTD**

Executive Vice President - Finance & Secretary